RANI
Price:
$2.41
Market Cap:
$135.94M
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatm...[Read more]
Industry
Biotechnology
IPO Date
2021-07-30
Stock Exchange
NASDAQ
Ticker
RANI
According to Rani Therapeutics Holdings, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 166.17M. This represents a change of 54.28% compared to the average of 107.71M of the last 4 quarters.
The mean historical Enterprise Value of Rani Therapeutics Holdings, Inc. over the last ten years is 184.18M. The current 166.17M Enterprise Value has changed 8.92% with respect to the historical average. Over the past ten years (40 quarters), RANI's Enterprise Value was at its highest in in the June 2021 quarter at 515.79B. The Enterprise Value was at its lowest in in the March 2020 quarter at 0.
Average
184.18M
Median
147.84M
Minimum
108.41M
Maximum
316.09M
Discovering the peaks and valleys of Rani Therapeutics Holdings, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 38.56%
Maximum Annual Enterprise Value = 316.09M
Minimum Annual Increase = -53.23%
Minimum Annual Enterprise Value = 108.41M
Year | Enterprise Value | Change |
---|---|---|
2023 | 108.41M | -24.57% |
2022 | 143.73M | -29.83% |
2021 | 204.84M | 38.56% |
2020 | 147.84M | -53.23% |
The current Enterprise Value of Rani Therapeutics Holdings, Inc. (RANI) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
152.33M
5-year avg
184.18M
10-year avg
184.18M
Rani Therapeutics Holdings, Inc.’s Enterprise Value is greater than Vincerx Pharma, Inc. (4.98M), greater than Tenaya Therapeutics, Inc. (147.56M), less than Corvus Pharmaceuticals, Inc. (550.07M), greater than ALX Oncology Holdings Inc. (80.42M), greater than Lyra Therapeutics, Inc. (22.05M), less than Trevi Therapeutics, Inc. (208.91M), greater than SQZ Biotechnologies Company (24.11M), greater than Protara Therapeutics, Inc. (-31165818.00), greater than TRACON Pharmaceuticals, Inc. (-6133696.00), greater than Vaccinex, Inc. (8.95M), greater than Monopar Therapeutics Inc. (81.10M), greater than Miromatrix Medical Inc. (90.06M), greater than Surrozen, Inc. (2.49M), less than Monte Rosa Therapeutics, Inc. (478.04M), greater than PMV Pharmaceuticals, Inc. (48.13M), less than Pharvaris N.V. (844.47M), less than Tyra Biosciences, Inc. (772.84M), greater than Molecular Partners AG (57.66M), greater than Cabaletta Bio, Inc. (24.18M), greater than Viracta Therapeutics, Inc. (12.72M), less than EyePoint Pharmaceuticals, Inc. (707.60M), less than Biomea Fusion, Inc. (241.97M),
Company | Enterprise Value | Market cap |
---|---|---|
4.98M | $11.06M | |
147.56M | $190.12M | |
550.07M | $564.21M | |
80.42M | $78.48M | |
22.05M | $17.21M | |
208.91M | $220.68M | |
24.11M | $12.83M | |
-31165818.00 | $53.43M | |
-6133696.00 | $136.30K | |
8.95M | $9.06M | |
81.10M | $87.22M | |
90.06M | $92.95M | |
2.49M | $38.09M | |
478.04M | $542.54M | |
48.13M | $84.49M | |
844.47M | $1.29B | |
772.84M | $865.93M | |
57.66M | $247.30M | |
24.18M | $195.39M | |
12.72M | $7.88M | |
707.60M | $775.07M | |
241.97M | $320.35M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rani Therapeutics Holdings, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Rani Therapeutics Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Rani Therapeutics Holdings, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Rani Therapeutics Holdings, Inc. (RANI)?
What is the 3-year average Enterprise Value for Rani Therapeutics Holdings, Inc. (RANI)?
What is the 5-year average Enterprise Value for Rani Therapeutics Holdings, Inc. (RANI)?
How does the current Enterprise Value for Rani Therapeutics Holdings, Inc. (RANI) compare to its historical average?